Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protective Efficacy of PvCSP Vaccine Against Plasmodium Vivax Malaria
NCT02083068Phase 2Completed
- Sponsor
- Malaria Vaccine and Drug Development Center
- Start
- Aug 2014
- Primary completion
- Sep 2015
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in malaria (2 arms), sponsored by Malaria Vaccine and Drug Development Center. Primary endpoint: Protective efficacy against P. vivax infection. Started Aug 2014; status: completed.
02
Conditions
malaria
Beyond the preview
Go deeper on NCT02083068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083068.